Members

After graduating from Hokkaido University, he joined Ajinomoto Co., Inc. While employed there, he earned his Doctor of Medical Science degree under Professor Kenichi Matsubara at the Center for Cell Engineering, Osaka University. Subsequently, he conducted research on the identification of tumor suppressor genes in breast and ovarian cancers at the Cancer Institute, Cancer Research Institute. He then pursued apoptosis research at the La Jolla Cancer Research Foundation (now Sanford-Burnham Medical Research Institute) in the United States, followed by research on mechanisms of cancer cell evasion of cell death at Columbia University College of Physicians and Surgeons. During this period, he concurrently served as Senior Researcher at the RIKEN Molecular Oncology Laboratory.
At Shimadzu Corporation, he held positions including Director of the Life Science Research Laboratory, Fellow, and Senior Fellow.

He currently serves as Specially Appointed Professor at the University of Tsukuba and Director of the Center for Precision Medicine Development and Research, while also holding visiting professor positions at Osaka Medical College and the Institute for Physiological Regulation at Gunma University.
His specialty is molecular oncology.

After graduating from Chiba University’s Faculty of Horticulture, he pursued graduate studies in fermentation engineering at Osaka University. As a researcher at Idemitsu Kosan Co., Ltd.’s Central Research Laboratories, he engaged in R&D utilizing genetic engineering. During his tenure, he served as a visiting researcher at the La Jolla Cancer Research Foundation in the United States, contributing to cancer research. After transferring to a domestic venture company, he became a visiting researcher at Columbia University College of Physicians and Surgeons. Subsequently, as a senior researcher at the RIKEN Molecular Oncology Laboratory, he tackled cutting-edge research in molecular oncology. Subsequently, as the representative of ILAMM, Inc., a company he founded, he dedicated himself to the societal implementation of research outcomes. Concurrently, he served as a Principal Researcher at Toppan Printing Co., Ltd., leading research and development within the industrial sector.

In recent years, he has been an Invited Associate Professor at the Graduate School of Engineering, Osaka University, focusing on nurturing the next generation of researchers. At iLAC Co., Ltd., he serves as Director and Chief Scientific Officer, leveraging his extensive research experience to connect scientific insights with business strategy.

After joining Japan Electron Optics Laboratory Co., Ltd., he worked in the Corporate Planning Department at headquarters before spending 10 years stationed at the U.S. subsidiary.
During this period, he was involved in establishing subsidiaries in North and Central/South America.
Subsequently, at SAP Japan, he served as CFO for North-East Asia before leading overall management as COO/Representative Director.
He contributed to the formation and expansion of the nascent ERP market in Japan.
At Philips Japan, he assumed the position of President and Representative Executive Officer, overseeing the Healthcare business and leading the Japanese subsidiary through a major global business restructuring.
At Kodak Japan, he served as President and Representative Director and Chairman of the Korean subsidiary, achieving 11 consecutive years of profitability and contributing to the headquarters’ restructuring.

Leveraging extensive experience as top management at international corporations, successfully shaping new markets, executing global business restructuring, and achieving relistings, he is now focused on strengthening overall management and business strategy.

Director, Wellness Sugar Co., Ltd. (2023–present); Outside Director, WAKUNAGA PHARMACEUTICAL CO., LTD. (2018–2022); INSEAD Executive MBA (2004).

After graduating from Otaru University of Commerce, joined Mitsubishi Corporation. During enrollment period, he was involved in the development and maintenance of SAP-based core business system, as well as productivity improvement and new business development leveraging DX expertise. These achievements were recognized, and he received the President’s Award. He also taught undergraduate and graduate students development methodologies for digital services based on insights from the business front lines as a part-time lecturer at Tokyo Institute of Technology’s School of Social and Engineering Sciences. Subsequently, he participated in establishing a private equity fund company in Singapore, driving a PE fund business specializing in Japanese companies’ overseas expansion.
Currently at Toyo Kohan Co., Ltd. (A main subsidiary of the Toyo Seikan Group), he drove organizational transformation and contributed to profit improvement as the Corporate Planning Officer, and head of the Magnetic Disk Business by formulating business strategies and implementing business reforms utilizing DX knowhows and technologies like AI.

Most recently, he is leading the manufacturing and sales business of genetic diagnostic agents as head of the Life Sciences Business of Toyo Kohan, while also spearheading new business opportunity creation at iLAC.

After graduating from Kyushu University Graduate School of Economics, joined Development Bank of Japan (DBJ, now Development Bank of Japan Inc.) in 2003.
After serving in the Research Department and Kyushu Branch, served as Investment Manager at DBJ Capital Inc. from 2007 (5 years).
Major exit achievements include Net Marketing Inc., SymBio Pharmaceuticals Ltd., and NanoCarrier Co., Ltd.
From 2012, he served in DBJ’s Corporate Finance Division 4, Accounting Department (concurrently in the Corporate Planning Department), and the Secretariat Office. From 2023, he served as Senior Vice President at DBJ Europe Limited.
From 2024, he is Deputy Director and Section Chief of the Innovation Investment Department. He is a certified tax accountant.

After graduating from the University of Tokyo, joined Development Bank of Japan Inc. in 2019.
After working in market operations and investment and financing for major corporations and startups in the chemical industry, currently serves as Research Officer in the Innovation Investment Department.

Appointed as an Executive Officer of the company in 2025.

He graduated from the Graduate School of Science and Technology and Professional Graduate School at Tokyo University of Science, earning a Master of Management of Technology (MOT). After joining Sharp Corporation, he engaged in the development and commercialization of protein analysis devices while conducting research on the cancer stem cells regulation of differentiation utilizing proteomics at the Graduate School of Medical Sciences, Kumamoto University, where he obtained a Ph.D. in Medical Science.
He later participated in the adipose-derived stem cell banking business at MTI Ltd. and took on business development and management roles at AI startups.
Subsequently, he served as Executive Manager of the Scientific Research Service Division at Rhelixa Inc., a provider of next-generation sequencing analysis services, he joined our company as Executive Officer at our company in August 2025.

After graduating from Waseda University’s Faculty of Science and Engineering, he joined Toppan Printing Co., Ltd. and earned a Doctor of Engineering degree. While at the company, he served as a visiting researcher at the National Research Council of Canada and a College Fellow at the University of Oxford before assuming the position of Director of the Oxford Toppan Centre for Nanomaterials. Domestically, he led the formulation of corporate technology strategy and new business creation as Head of R&D Strategy. As a Director of the U.S. venture company E Ink Holdings, Inc., he drove the development and commercialization of electronic paper. Subsequently, as President and CEO of RIKEN GENESIS, he spearheaded the clinical application of genetic testing, significantly contributing to business expansion and industrialization in the biotechnology field.

Currently, he serves as Director and Head of the Head of Corporate Strategy at Ball Wave Inc., responsible for formulating and executing management strategies, while currently serving as Auditor at iLAC Corporation. Leveraging his extensive experience as an executive and expertise in research and development, he drives the commercialization of cutting-edge technologies and enhances corporate value. Recipient of the IEEE UFFC Best Paper Award.

After completing his doctoral studies at the Graduate School of Chemistry, Tokyo University, he served as an assistant professor at Kanazawa University School of Medicine and Kyushu University School of Medicine. He then pursued research as a fellow at Harvard University’s Department of Biology and Stanford University School of Medicine. Upon returning to Japan, he served as Associate Professor at Kyushu University School of Medicine and Professor at Osaka University School of Medicine. He also held positions as Director of the Molecular Genetics Research Facility and Professor and Director of the Osaka University Center for Cell Engineering. He played a pioneering role in developing the hepatitis B virus vaccine and as the first Vice President of the International Human Genome Organization, driving the Human Genome Project forward. He made significant contributions to both basic research and industrial applications in the life sciences field, including founding DNA Chip Laboratory Co., Ltd. in 1999.
He received the Minister of Health and Welfare Commendation, the Princess Takamatsu Cancer Research Fund Academic Award, the Science and Technology Agency Director-General’s Award, and the Medal with Purple Ribbon. Selected as a Person of Cultural Merit in 2006 and awarded the Order of Culture in 2017, he is a leading pioneer in molecular biology and genome research representing Japan.